Date published: 2026-6-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

BMY 45778 (CAS 152575-66-1)

0.0(0)
Write a reviewAsk a question

Application:
BMY 45778 is a partial agonist at IP prostacyclin receptors
CAS Number:
152575-66-1
Molecular Weight:
438.44
Molecular Formula:
C26H18N2O5
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

BMY 45778 is a partial agonist at IP prostacyclin receptors that is a non-prostanoid prostacyclin mimetic. Also shown to inhibit platelet aggregation in vitro.


BMY 45778 (CAS 152575-66-1) References

  1. Non-prostanoid prostacyclin mimetics as neuronal stimulants in the rat: comparison of vagus nerve and NANC innervation of the colon.  |  Rudd, JA., et al. 2000. Br J Pharmacol. 129: 782-90. PMID: 10683203
  2. Prostacyclin IP receptor up-regulates the early expression of C/EBPbeta and C/EBPdelta in preadipose cells.  |  Aubert, J., et al. 2000. Mol Cell Endocrinol. 160: 149-56. PMID: 10715548
  3. Factors affecting prostacyclin receptor agonist efficacy in different cell types.  |  Kam, Y., et al. 2001. Cell Signal. 13: 841-7. PMID: 11583920
  4. Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics.  |  Chow, KB., et al. 2001. Br J Pharmacol. 134: 1375-84. PMID: 11724742
  5. The effect of prostacyclin agonists on the differentiation of phorbol ester treated human erythroleukemia cells.  |  Shen, HW., et al. 2007. Prostaglandins Other Lipid Mediat. 83: 231-6. PMID: 17481561
  6. Evidence for a second receptor for prostacyclin on human airway epithelial cells that mediates inhibition of CXCL9 and CXCL10 release.  |  Wilson, SM., et al. 2011. Mol Pharmacol. 79: 586-95. PMID: 21173040
  7. Anodal iontophoresis of a soluble guanylate cyclase stimulator induces a sustained increase in skin blood flow in rats.  |  Kotzki, S., et al. 2013. J Pharmacol Exp Ther. 346: 424-31. PMID: 23838678
  8. Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid.  |  Meanwell, NA., et al. 1993. J Med Chem. 36: 3884-903. PMID: 7504734
  9. A study of prostacyclin mimetics distinguishes neuronal from neutrophil IP receptors.  |  Wise, H., et al. 1995. Eur J Pharmacol. 278: 265-9. PMID: 7589166
  10. The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function.  |  Wise, H. 1996. Prostaglandins Leukot Essent Fatty Acids. 54: 351-60. PMID: 8832764
  11. [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding.  |  Seiler, SM., et al. 1997. Prostaglandins. 53: 21-35. PMID: 9068064
  12. Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery.  |  Jones, RL., et al. 1997. J Cardiovasc Pharmacol. 29: 525-35. PMID: 9156364
  13. Characterization of a prostanoid EP3-receptor in guinea-pig aorta: partial agonist action of the non-prostanoid ONO-AP-324.  |  Jones, RL., et al. 1998. Br J Pharmacol. 125: 1288-96. PMID: 9863659

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

BMY 45778, 10 mg

sc-361127
10 mg
$183.00

BMY 45778, 50 mg

sc-361127A
50 mg
$769.00